Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study

Breast Cancer Research and Treatment

Volumn 167, Issue 3, 2018, Pages 671-686

  Dirix, Luc Y ^a   Takacs, Istvan ^b   Jerusalem, Guy ^c   Nikolinakos, Petros ^d   Arkenau, Hendrik Tobias ^e,f   Forero Torres, Andres ^g   Boccia, Ralph ^h   Lippman, Marc E ⁱ   Somer, Robert ^j   Smakal, Martin ^k   Emens, Leisha A ^l   Hrinczenko, Borys ^m   Edenfield, William ⁿ   Gurtler, Jayne ^o   von Heydebreck, Anja ^p   Grote, Hans Juergen ^p   Chin, Kevin ^q   Hamilton, Erika P ^r  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d University Cancer and Blood Center   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Center for Cancer and Blood Disorders   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^k Chirurgické Oddelení Nemocnice Ho ovice A s   (Czech Republic)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MICHIGAN STATE UNIVERSITY   (United States)

ⁿ GREENVILLE HOSPITAL SYSTEM   (United States)

^o Metairie Oncologists   (United States)

^p MERCK KGAA   (Germany)

^q EMD Serono   (United States)

^r SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

Avelumab; Metastatic breast cancer; PD L1; Second line; Triple negative breast cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AVELUMAB; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; EVEROLIMUS; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; IXABEPILONE; LAPATINIB; METHOTREXATE; ONARTUZUMAB; PACLITAXEL; PERTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VELIPARIB; VINORELBINE TARTRATE; ANTIIDIOTYPIC ANTIBODY; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATAXIA; ATRIAL FIBRILLATION; AUTOIMMUNE HEPATITIS; BACKACHE; BODY WEIGHT LOSS; BRAIN INJURY; BREAST CANCER; BRONCHUS OBSTRUCTION; BURNING SENSATION; CANCER PAIN; CANCER RADIOTHERAPY; CARDIOPULMONARY INSUFFICIENCY; CELLULITIS; CHOLESTASIS; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DENTAL CARIES; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRY EYE; DRY SKIN; DYSPNEA; FAILURE TO THRIVE; FATIGUE; FEMALE; FEVER; FLANK PAIN; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION DETERIORATION; HEADACHE; HEART ARREST; HEART FAILURE; HEART TAMPONADE; HEMATURIA; HEMOPTYSIS; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HIP PAIN; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFECTION; INFUSION RELATED REACTION; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; JUGULAR VEIN THROMBOSIS; LEG PAIN; LIMB PAIN; LIVER DISEASE; LIVER METASTASIS; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MALIGNANT PLEURA EFFUSION; MALNUTRITION; METASTASIS; MONOPLEGIA; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NECK PAIN; NEUTROPENIA; NEUTROPHIL COUNT; NONCARDIAC CHEST PAIN; OBSTRUCTIVE UROPATHY; OPEN STUDY; PAPULAR RASH; PARAPLEGIA; PATHOLOGIC FRACTURE; PEMPHIGOID; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLATELET COUNT; PLEURA EFFUSION; PLEURAL PAIN; PNEUMONIA; PNEUMOTHORAX; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; PULMONARY HYPERTENSION; QT PROLONGATION; RADIATION PNEUMONIA; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SINUS TACHYCARDIA; SPINAL CORD COMPRESSION; THORAX PAIN; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85031927832     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4537-5     Document Type: Article

References (34)

1. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29
2. National Cancer Institute (2016) SEER cancer stat facts: female breast cancer. National Cancer Institute, Bethesda, p 2016
3. National Comprehensive Cancer Network (V2 2017) (2017) NCCN clinical practice guidelines in oncology: breast cancer. National Comprehensive Cancer Network, Orlando
4. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434
5. Anders CK, Abramson V, Tan T et al (2016) The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book 35:34–42
6. Andre F, Zielinski CC (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:46–51
7. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982
8. Mittendorf EA, Philips AV, Meric-Bernstam F et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:361–370
9. Schalper KA, Velcheti V, Carvajal D et al (2014) In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773–2782
10. Wimberly H, Brown JR, Schalper K et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3:326–332
11. Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800
12. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034
13. Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297
14. Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59
15. Cimino-Mathews A, Thompson E, Taube JM et al (2016) PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 47:52–63
16. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461
17. Nanda R, Chow LQ, Dees EC et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460–2467
18. Emens L, Braiteh F, Cassier P et al (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res 75:2859
19. Schmid P, Cruz C, Braiteh FS et al (2017) Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analysis. Cancer Res 77:2986
20. Heery CR, O’Sullivan-Coyne G, Madan RA et al (2017) Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–597
21. Boyerinas B, Jochems C, Fantini M et al (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3:1148–1157
22. Fujii R, Friedman ER, Richards J et al (2016) Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget 7:33498–33511
23. Grenga I, Donahue RN, Lepone LM et al (2016) A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol 5:e83
24. Kaufman HL, Russell J, Hamid O et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374–1385
25. Gulley JL, Rajan A, Spigel DR et al (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18:599–610
26. Apolo AB, Infante JR, Balmanoukian A et al (2017) Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 35:2117–2124
27. Bavencio (avelumab) injection [package insert] (2017) Darmstadt. Merck KGaA, Darmstadt
28. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
29. Donahue RN, Lepone LM, Grenga I et al (2017) Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer 5:13
30. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856
31. Wang X, Teng F, Kong L et al (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023–5039
32. Hirsch FR, McElhinny A, Stanforth D et al (2016) PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the “blueprint PD-L1 IHC assay comparison project”. J Thorac Oncol 12:208–222
33. Adams S, Diamond J, Hamiton E et al (2016) Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 34:1009
34. Tolaney S, Savulsky C, Aktan G et al (2017) Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Eur J Cancer 72:S16